ViroPharma PT Raised to $47.00 (VPHM)
Analysts at Stifel Nicolaus raised their target price on shares of ViroPharma (NASDAQ:VPHM) from $41.00 to $47.00 in a research report issued to clients and investors on Monday, ARN reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 20.11% from the company’s current price.
A number of other analysts have also recently weighed in on VPHM. Analysts at Oppenheimer raised their price target on shares of ViroPharma (NASDAQ:VPHM) from $44.00 to $54.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “fair value” rating on shares of ViroPharma (NASDAQ:VPHM) in a research note to investors on Friday. They now have a $52.00 price target on the stock. Finally, analysts at Wells Fargo & Co. downgraded shares of ViroPharma (NASDAQ:VPHM) from an “outperform” rating to a “market perform” rating in a research note to investors on Friday.
Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $39.14.
ViroPharma (NASDAQ:VPHM) opened at 39.13 on Monday. ViroPharma has a one year low of $22.12 and a one year high of $39.56. The stock has a 50-day moving average of $31.2 and a 200-day moving average of $27.98. The company’s market cap is $2.564 billion.
ViroPharma (NASDAQ:VPHM) last announced its earnings results on Thursday, August 1st. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter in the prior year, the company posted ($0.06) earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. On average, analysts predict that ViroPharma will post $-0.78 earnings per share for the current fiscal year.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.